• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

遗传性转甲状腺素蛋白淀粉样变性概述。

Hereditary transthyretin amyloidosis overview.

机构信息

Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Via S. Pansini, 5, 80131, Naples, Italy.

Section of Neurology, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

出版信息

Neurol Sci. 2022 Dec;43(Suppl 2):595-604. doi: 10.1007/s10072-020-04889-2. Epub 2020 Nov 14.

DOI:10.1007/s10072-020-04889-2
PMID:33188616
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9780126/
Abstract

Hereditary amyloidogenic transthyretin (ATTRv) amyloidosis is a rare autosomal dominantly inherited disorder caused by mutations in the transthyretin (TTR) gene. The pathogenetic model of ATTRv amyloidosis indicates that amyloidogenic, usually missense, mutations destabilize the native TTR favouring the dissociation of the tetramer into partially unfolded species that self-assemble into amyloid fibrils. Amyloid deposits and monomer-oligomer toxicity are the basis of multisystemic ATTRv clinical involvement. Peripheral nervous system (autonomic and somatic) and heart are the most affected sites. In the last decades, a better knowledge of pathomechanisms underlying the disease led to develop novel and promising drugs that are rapidly changing the natural history of ATTRv amyloidosis. Thus, clinicians face the challenge of timely diagnosis for addressing patients to appropriate treatment. As well, the progressive nature of ATTRv raises the issue of presymptomatic testing and risk management of carriers. The main aim of this review was to focus on what we know about ATTRv so far, from pathogenesis to clinical manifestations, diagnosis and hence patient's monitoring and treatment, and from presymptomatic testing to management of carriers.

摘要

遗传性转甲状腺素蛋白淀粉样变(ATTRv)是一种罕见的常染色体显性遗传性疾病,由转甲状腺素蛋白(TTR)基因的突变引起。ATTRv 淀粉样变的发病机制模型表明,淀粉样变性的,通常是错义,突变会使天然 TTR 不稳定,有利于四聚体解离成部分展开的物种,这些物种会自我组装成淀粉样纤维。淀粉样沉积物和单体-寡聚物毒性是 ATTRv 多系统临床受累的基础。周围神经系统(自主和躯体)和心脏是最受影响的部位。在过去的几十年中,对疾病发病机制的更好了解导致了新型有前途的药物的开发,这些药物正在迅速改变 ATTRv 淀粉样变的自然病史。因此,临床医生面临着及时诊断的挑战,以便为患者提供适当的治疗。此外,ATTRv 的进行性特征提出了对携带者进行无症状检测和风险管理的问题。本综述的主要目的是聚焦于迄今为止我们对 ATTRv 的了解,从发病机制到临床表现、诊断,进而到患者的监测和治疗,以及从无症状检测到携带者的管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b7/9780126/ddbfdde6ee71/10072_2020_4889_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b7/9780126/ddbfdde6ee71/10072_2020_4889_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0b7/9780126/ddbfdde6ee71/10072_2020_4889_Fig1_HTML.jpg

相似文献

1
Hereditary transthyretin amyloidosis overview.遗传性转甲状腺素蛋白淀粉样变性概述。
Neurol Sci. 2022 Dec;43(Suppl 2):595-604. doi: 10.1007/s10072-020-04889-2. Epub 2020 Nov 14.
2
Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.遗传性转甲状腺素蛋白淀粉样变性病诊断与管理的新方法。
J Neurol Neurosurg Psychiatry. 2022 Jun;93(6):668-678. doi: 10.1136/jnnp-2021-327909. Epub 2022 Mar 7.
3
Hereditary Transthyretin Amyloidosis and the Impact of Classic and New Treatments on Kidney Function: A Review.遗传性转甲状腺素蛋白淀粉样变性病和经典及新型治疗方法对肾功能的影响:综述。
Am J Kidney Dis. 2024 Aug;84(2):224-231. doi: 10.1053/j.ajkd.2024.01.527. Epub 2024 Mar 12.
4
Hereditary Transthyretin Amyloidosis遗传性转甲状腺素蛋白淀粉样变性
5
A natural history analysis of asymptomatic gene carriers as they develop symptomatic transthyretin amyloidosis in the Transthyretin Amyloidosis Outcomes Survey (THAOS).在转甲状腺素蛋白淀粉样变性病结局研究(THAOS)中,对无症状基因携带者出现症状性转甲状腺素蛋白淀粉样变性病的自然史进行分析。
Amyloid. 2022 Dec;29(4):228-236. doi: 10.1080/13506129.2022.2070470. Epub 2022 Jun 22.
6
Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.治疗转甲状腺素蛋白淀粉样变(ATTRv)神经病的药物和基因治疗。
Curr Neuropharmacol. 2023;21(3):471-481. doi: 10.2174/1570159X21666221108094736.
7
The neuropathy in hereditary transthyretin amyloidosis: A narrative review.遗传性转甲状腺素蛋白淀粉样变性神经病:叙述性综述。
J Peripher Nerv Syst. 2021 Jun;26(2):155-159. doi: 10.1111/jns.12451. Epub 2021 May 11.
8
Amyloid Neuropathy: From Pathophysiology to Treatment in Light-Chain Amyloidosis and Hereditary Transthyretin Amyloidosis.淀粉样变神经病:轻链淀粉样变和遗传性转甲状腺素蛋白淀粉样变中的病理生理学到治疗。
Ann Neurol. 2024 Sep;96(3):423-440. doi: 10.1002/ana.26965. Epub 2024 Jun 24.
9
Corneal confocal microscopy identifies corneal nerve loss and increased Langerhans cells in presymptomatic carriers and patients with hereditary transthyretin amyloidosis.角膜共焦显微镜可识别出遗传性转甲状腺素蛋白淀粉样变性症的无症状携带者和患者的角膜神经丢失和朗格汉斯细胞增加。
J Neurol. 2023 Jul;270(7):3483-3491. doi: 10.1007/s00415-023-11689-z. Epub 2023 Apr 4.
10
Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.遗传性转甲状腺素蛋白淀粉样变性病:致命疾病的医学进步典范。
Nat Rev Neurol. 2019 Jul;15(7):387-404. doi: 10.1038/s41582-019-0210-4. Epub 2019 Jun 17.

引用本文的文献

1
Parallel Neurological and Cardiac Progression in Hereditary Transthyretin Amyloidosis: An Integrated Clinical and Imaging Study.遗传性转甲状腺素蛋白淀粉样变性的神经与心脏平行进展:一项综合临床与影像学研究
Diagnostics (Basel). 2025 Aug 25;15(17):2143. doi: 10.3390/diagnostics15172143.
2
Real-World Characteristics and Treatment Patterns of Patients With Transthyretin Amyloid Cardiomyopathy: Protocol for a Multicountry Disease Registry Study.转甲状腺素蛋白淀粉样变心肌病患者的真实世界特征与治疗模式:一项多国疾病登记研究方案
JMIR Res Protoc. 2025 Jun 6;14:e71314. doi: 10.2196/71314.
3
Inherited transthyretin cardiac amyloidosis presenting with diastolic heart failure and gastrointestinal symptoms: a case report and literature review.

本文引用的文献

1
Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis.转甲状腺素蛋白变异型淀粉样变性患者的循环微小RNA谱
Front Mol Neurosci. 2020 Jun 23;13:102. doi: 10.3389/fnmol.2020.00102. eCollection 2020.
2
Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.托卡朋,一种有效的聚集抑制剂,用于治疗家族性脑脊髓液淀粉样变性病。
FEBS J. 2021 Jan;288(1):310-324. doi: 10.1111/febs.15339. Epub 2020 May 11.
3
Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care.
以舒张性心力衰竭和胃肠道症状为表现的遗传性转甲状腺素蛋白心脏淀粉样变性:一例报告及文献复习
Front Cardiovasc Med. 2025 May 8;12:1588291. doi: 10.3389/fcvm.2025.1588291. eCollection 2025.
4
Genetic Screening for Hereditary Transthyretin Amyloidosis in the Population of Cammarata and San Giovanni Gemini Through Red Flags and Registry Archives.通过警示信号和登记档案对坎马腊塔和圣乔瓦尼吉米尼人群中的遗传性转甲状腺素蛋白淀粉样变性进行基因筛查。
Brain Sci. 2025 Mar 31;15(4):365. doi: 10.3390/brainsci15040365.
5
Hereditary cardiac amyloidosis associated with a rare p.Ala101Val transthyretin mutation: a case description.与罕见的甲状腺素运载蛋白p.Ala101Val突变相关的遗传性心脏淀粉样变性:病例描述
Quant Imaging Med Surg. 2025 Mar 3;15(3):2625-2631. doi: 10.21037/qims-24-1542. Epub 2025 Jan 20.
6
The deLIVERed promises of gene therapy: Past, present, and future of liver-directed gene therapy.基因治疗的兑现承诺:肝脏定向基因治疗的过去、现在与未来
Mol Ther. 2025 May 7;33(5):1966-1987. doi: 10.1016/j.ymthe.2025.03.041. Epub 2025 Mar 27.
7
NfL as a biomarker in ATTRv amyloidosis: potential and limitations.神经丝轻链作为转甲状腺素蛋白淀粉样变的生物标志物:潜力与局限性
Neurol Sci. 2025 Mar 19. doi: 10.1007/s10072-025-08110-0.
8
Expanding the Genetic and Clinical Spectrum of Hereditary Transthyretin Amyloidosis: The Glu61Ala Variant.扩大遗传性转甲状腺素蛋白淀粉样变性的基因和临床谱:Glu61Ala变异体
J Pers Med. 2025 Feb 6;15(2):61. doi: 10.3390/jpm15020061.
9
Hereditary Transthyretin Amyloidosis in Israel: Genetic Landscape and Clinical Characteristics.以色列的遗传性转甲状腺素蛋白淀粉样变性:基因图谱与临床特征
Eur J Neurol. 2025 Feb;32(2):e70057. doi: 10.1111/ene.70057.
10
Serum Biomarkers in Transthyretin Amyloidosis: An Overview of Neurofilaments, Cardiac, Renal, and Gastrointestinal Involvement.转甲状腺素蛋白淀粉样变性中的血清生物标志物:神经丝、心脏、肾脏和胃肠道受累概述
Neurol Ther. 2025 Feb;14(1):71-84. doi: 10.1007/s40120-024-00696-5. Epub 2025 Jan 3.
遗传性转甲状腺素蛋白淀粉样变性(hATTR)多发性神经病的诊断与治疗:改善患者护理的当前观点
Ther Clin Risk Manag. 2020 Feb 21;16:109-123. doi: 10.2147/TCRM.S219979. eCollection 2020.
4
Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy?转甲状腺素蛋白淀粉样变性症的新兴治疗方法 - 在多年停滞之后迎来新希望?
Eur J Heart Fail. 2020 Jan;22(1):39-53. doi: 10.1002/ejhf.1695. Epub 2020 Jan 7.
5
Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.改善多发性神经病ATTR 淀粉样变症诊断的专家共识建议。
J Neurol. 2021 Jun;268(6):2109-2122. doi: 10.1007/s00415-019-09688-0. Epub 2020 Jan 6.
6
Peripheral neuropathy: Clinical pearls for making the diagnosis.周围神经病变:诊断的实用要点
JAAPA. 2020 Jan;33(1):9-15. doi: 10.1097/01.JAA.0000615460.45150.e0.
7
Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis.骨闪烁显像检测 Phe64Leu 突变相关转甲状腺素蛋白心脏淀粉样变的灵敏度低。
JACC Cardiovasc Imaging. 2020 Jun;13(6):1314-1321. doi: 10.1016/j.jcmg.2019.10.015. Epub 2019 Dec 18.
8
Amyloidosis and Ocular Involvement: an Overview.淀粉样变性和眼部受累:概述。
Semin Ophthalmol. 2020 Jan 2;35(1):7-26. doi: 10.1080/08820538.2019.1687738. Epub 2019 Dec 12.
9
Scientific Advances in and Clinical Approaches to Small-Fiber Polyneuropathy: A Review.小纤维多发性神经病的科学进展与临床治疗方法:综述
JAMA Neurol. 2019 Oct 1;76(10):1240-1251. doi: 10.1001/jamaneurol.2019.2917.
10
Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7.遗传性转甲状腺素蛋白淀粉样变多发性神经病损伤测量指标的发展:从神经病变损害评分(NIS)到改良神经病变损害评分(mNIS)+7。
J Neurol Sci. 2019 Oct 15;405:116424. doi: 10.1016/j.jns.2019.116424. Epub 2019 Aug 8.